Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis

Bruno Vincenzi, Margherita Nannini, Elena Fumagalli, Giuseppe Bronte, Anna Maria Frezza, Delia De Lisi, Mariella Spalato Ceruso, Daniele Santini, Giuseppe Badalamenti, Maria Abbondanza Pantaleo, Antonio Russo, Angelo Paolo Dei Tos, Paolo Casali, Giuseppe Tonini

Research output: Contribution to journalArticle

Abstract

We retrospectively reviewed data from 123 patients (KIT exon 11 mutated) who received sunitinib or dose-escalated imatinib as second line. All patients progressed on imatinib (400 mg/die) and received a second line treatment with imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 offor 37.5 mg/day). Deletion versus other KIT 11 mutation was recorded, correlated with clinical benefits. 64% received imatinib, 36% sunitinib. KIT exon 11 mutation was available in 94 patients. With a median follow-up of 61 months, median time to progression (TTP) in patients receiving sunitinib and imatinib was 10 (95% CI 9.7-10.9) and 5 months (95% CI 3.6-6.7) respectively (P = 0.012). No difference was found in overall survival (OS) (P = 0.883). In imatinib arm, KIT exon 11 deletions was associated with a shorter TTP (7 vs 17 months; P = 0.02), with a trend in OS (54 vs 71 months P = 0.063). No difference was found in patients treated with sunitinib (P = 0.370). A second line with sunitinib was associated with an improved TTP in KIT exon 11 mutated patients progressing on imatinib 400 mg/die. Deletions in exon 11 seemed to be correlated with worse outcome in patients receiving imatinib-based second line.

Original languageEnglish
Pages (from-to)69412-69419
Number of pages8
JournalOncotarget
Volume7
Issue number43
DOIs
Publication statusPublished - 2016

Keywords

  • Exon 11
  • GIST
  • Imatinib
  • Second line
  • Sunitinib

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis'. Together they form a unique fingerprint.

  • Cite this

    Vincenzi, B., Nannini, M., Fumagalli, E., Bronte, G., Frezza, A. M., De Lisi, D., Ceruso, M. S., Santini, D., Badalamenti, G., Pantaleo, M. A., Russo, A., Dei Tos, A. P., Casali, P., & Tonini, G. (2016). Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis. Oncotarget, 7(43), 69412-69419. https://doi.org/10.18632/oncotarget.5136